Chairman of the New York Angels and Founder of Launch.it
Co-Founder and President, Institute for Systems Biology
Founder & Chief Medical Officer, Vidacare Corporation
Associate member, Fred Hutchinson Cancer Research Center.
Founder and CEO, Vokl
Chief business officer, Genoa Pharmaceuticals
Managing Director, Santé Ventures
Dan Shapiro, Entrepreneur in Residence, Google
|
|
La Jolla Pharmaceutical (NASDAQ: LJPC) has formed a partnership to co-develop its experimental drug for lupus of the kidneys, Riquent, with Novato, CA-based BioMarin Pharmaceuticals (NASDAQ: BMRN). La Jolla will receive a $15 million upfront payment, and could stand to get $289 million in cash and equity from BioMarin if the drug reaches certain development goals. The medicine is in the final stage of clinical trials.
San Francisco · 6/3/13
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
